MYC and esophageal squamous cell carcinoma: Based on our results showing that c-Myc was reduced in cells treated with trametinib and iMDK, we postulate that c-Myc is an important ERK-dependent downstream effector of the SRGN-MDK/ERK axis in ESCC cells.